Josep Figueras-Aloy

Josep Figueras-Aloy

Auto-generated profile, based on publicly available information

Josep Figueras-Aloy

Hospital Clínic, Catedràtic de Pediatria, Universitat de Barcelona, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
LBLouis Bont
Louis Bont
PCPaul A. Checchia
Paul A. Checchia
BFBrigitte Fauroux
Brigitte Fauroux
JFJosep Figueras-Aloy
Josep Figueras-Aloy
PMPaolo Manzoni
Paolo Manzoni
Xavier Carbonell-EstranyXavier Carbonell-Estrany
Xavier Carbonell-Estrany
Introduction The REGAL (RSV [respiratory syncytial virus] Evidence—a Geographical Archive of the Literature) series provides a comprehensive review of the published evidence in the field of RSV in Western countries over the last 20 years. This first of seven publications covers the epidemiology and burden of RSV infection. Methods A systematic review was undertaken for articles published between Jan 1, 1995 and Dec 31, 2015 across PubMed, Embase, The Cochrane Library, and Clinicaltrials.gov. Studies reporting data for hospital visits/admissions for RSV infection among children (≤18 years of age), as well as studies reporting RSV-associated morbidity, mortality, and risk factors were included. Study quality and strength of evidence (SOE) were graded using recognized criteria. Result 2315 studies were identified of which 98 were included. RSV was associated with 12–63% of all acute respiratory infections (ARIs) and 19–81% of all viral ARIs causing hospitalizations in children (high SOE). Annual RSV hospitalization (RSVH) rates increased with decreasing age and varied by a factor of 2–3 across seasons (high SOE). Studies were conflicting on whether the incidence of RSVH has increased, decreased, or remained stable over the last 20 years (moderate SOE). Length of hospital stay ranged from 2 to 11 days, with 2–12% of cases requiring intensive care unit admission (moderate SOE). Case-fatality rates were <0.5% (moderate SOE). Risk factors associated with RSVH included: male sex; age <6 months; birth during the first half of the RSV season; crowding/siblings; and day-care exposure (high SOE). Conclusion RSV infection remains a major burden on Western healthcare systems and has been associated with significant morbidity. Further studies focusing on the epidemiology of RSV infection (particularly in the outpatient setting), the impact of co-infection, better estimates of case-fatality rates and associated risk factors (all currently moderate/low SOE) are needed to determine the true burden of disease. Funding Abbvie.

1 October 2016 in The Journal of Pediatrics
Verified
Journal Article
Closed access
PSPrakesh S Shah
Prakesh S Shah
KLKei Lui
Kei Lui
GSGunnar Sjörs
Gunnar Sjörs
LMLucia Mirea
Lucia Mirea
BRBrian Reichman
Brian Reichman
INInternational Network for Evaluating Outcomes (iNeo) of Neonates
International Network for Evaluating Outcomes (iNeo) of Neonates

29 March 2017 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
BFBrigitte Fauroux
Brigitte Fauroux
ESEric A. F. Simões
Eric A. F. Simões
PCPaul A. Checchia
Paul A. Checchia
BPBosco Paes
Bosco Paes
JFJosep Figueras-Aloy
Josep Figueras-Aloy
Xavier Carbonell-EstranyXavier Carbonell-Estrany
Xavier Carbonell-Estrany
Introduction The REGAL (RSV Evidence—a Geographical Archive of the Literature) series provide a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. The objective of this fifth publication was to determine the long-term respiratory morbidity associated with RSV lower respiratory tract infection (RSV LRTI) in early life. Methods A systematic review was undertaken for articles published between January 1, 1995 and December 31, 2015. This was supplemented by inclusion of papers published whilst drafting the manuscript. Studies reporting data on the incidence and long-term wheezing and asthma following RSV LRTI in early life were included. Study quality and strength of evidence (SOE) were graded using recognized criteria. Results A total of 2337 studies were identified of which 74 were included. Prospective, epidemiologic studies consistently demonstrated that RSV LRTI is a significant risk factor for on-going respiratory morbidity characterized by transient early wheezing and recurrent wheezing and asthma within the first decade of life and possibly into adolescence and adulthood (high SOE). RSV LRTI was also associated with impaired lung function in these children (high SOE). Respiratory morbidity has been shown to result in reduced quality of life and increased healthcare resource use (moderate SOE). The mechanisms through which RSV contributes to wheezing/asthma development are not fully understood, but appear to relate to the viral injury, preexisting abnormal lung function and/or other factors that predispose to wheezing/asthma, including genetic susceptibility, altered immunology, eosinophilia, and associated risk factors such as exposure to environmental tobacco smoke (high SOE). Conclusion There is growing evidence that RSV LRTI in early childhood is associated with long-term wheezing and asthma and impaired lung function. Future research should aim to fully elucidate the pathophysiological mechanisms through which RSV causes recurrent wheezing/asthma.

1 February 2018 in Pediatrics
Verified
Journal Article
Open access
PDF file
JVJose Villar
Jose Villar
FGFrancesca Giuliani
Francesca Giuliani
FBFernando Barros
Fernando Barros
PRPaola Roggero
Paola Roggero
IZIrma Alejandra Coronado Zarco
Irma Alejandra Coronado Zarco
SKStephen Kennedy
Stephen Kennedy
There is no consensus regarding how the growth of preterm infants should be monitored or what constitutes their ideal pattern of growth, especially after term-corrected age. The concept that the growth of preterm infants should match that of healthy fetuses is not substantiated by data and, in practice, is seldom attained, particularly for very preterm infants. Hence, by hospital discharge, many preterm infants are classified as postnatal growth–restricted. In a recent systematic review, 61 longitudinal reference charts were identified, most with considerable limitations in the quality of gestational age estimation, anthropometric measures, feeding regimens, and how morbidities were described. We suggest that the correct comparator for assessing the growth of preterm infants, especially those who are moderately or late preterm, is a cohort of preterm newborns (not fetuses or term infants) with an uncomplicated intrauterine life and low neonatal and infant morbidity. Such growth monitoring should be comprehensive, as recommended for term infants, and should include assessments of postnatal length, head circumference, weight/length ratio, and, if possible, fat and fat-free mass. Preterm postnatal growth standards meeting these criteria are now available and may be used to assess preterm infants until 64 weeks’ postmenstrual age (6 months’ corrected age), the time at which they overlap, without the need for any adjustment, with the World Health Organization Child Growth Standards for term newborns. Despite remaining nutritional gaps, 90% of preterm newborns (ie, moderate to late preterm infants) can be monitored by using the International Fetal and Newborn Growth Consortium for the 21st Century Preterm Postnatal Growth Standards from birth until life at home.

22 February 2018 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
ESEric A. F. Simões
Eric A. F. Simões
LBLouis Bont
Louis Bont
PMPaolo Manzoni
Paolo Manzoni
BFBrigitte Fauroux
Brigitte Fauroux
BPBosco Paes
Bosco Paes
Xavier Carbonell-EstranyXavier Carbonell-Estrany
Xavier Carbonell-Estrany
Introduction The REGAL (RSV Evidence – A Geographical Archive of the Literature) series has provided a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. This seventh and final publication covers the past, present and future approaches to the prevention and treatment of RSV infection among infants and children. Methods A systematic review was undertaken of publications between January 1, 1995 and December 31, 2017 across PubMed, Embase and The Cochrane Library. Studies reporting data on the effectiveness and tolerability of prophylactic and therapeutic agents for RSV infection were included. Study quality and strength of evidence (SOE) were graded using recognized criteria. A further nonsystematic search of the published literature and Clinicaltrials.gov on antiviral therapies and RSV vaccines currently in development was also undertaken. Results The systematic review identified 1441 studies of which 161 were included. Management of RSV remains centered around prophylaxis with the monoclonal antibody palivizumab, which has proven effective in reducing RSV hospitalization (RSVH) in preterm infants < 36 weeks’ gestational age (72% reduction), children with bronchopulmonary dysplasia (65% reduction), and infants with hemodynamically significant congenital heart disease (53% reduction) (high SOE). Palivizumab has also shown to be effective in reducing recurrent wheezing following RSVH (high SOE). Treatment of RSV with ribavirin has conflicting success (moderate SOE). Antibodies with increased potency and extended half-life are currently entering phase 3 trials. There are approximately 15 RSV vaccines in clinical development targeting the infant directly or indirectly via the mother. Conclusion Palivizumab remains the only product licensed for RSV prophylaxis, and only available for high-risk infants. For the general population, there are several promising vaccines and monoclonal antibodies in various stages of clinical development, with the aim to significantly reduce the global healthcare impact of this common viral infection. Funding AbbVie.

1 September 2004 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
JFJosé Figueras-Aloy
José Figueras-Aloy
XCXavier Carbonell-Estrany
Xavier Carbonell-Estrany
JQJosé Quero
José Quero
IGIRIS Study Group
IRIS Study Group
The aim of this study was to identify those risk factors most likely to lead to the development of RSV-related respiratory Infection and subsequent hospital admission among premature infants born at 33–35 WGA (FLIP study) This was a prospective case-control study. Cases (186) hospitalized for respiratory syncytial virus (RSV) illness were recruited from 50 participating Spanish hospitals during the 2002–2003 RSV season (October 2002–April 2003). Controls (371) were selected in June 2003 but born at same time as cases. Of these cases, 20.5% were admitted to the intensive care unit intensive care unit, and 7.6% required mechanical ventilation. None of the patients died. Conditional logistic regression analysis adjusted for medical center demonstrated that the risk of RSV-related respiratory infection requiring hospital admission in preterm infants 33–35 weeks of gestation (WGA) in Spain was most often associated with absolute chronologic age at start of RSV season ≤10 weeks [ie, born between July 15 and December 15; odds ratio (OR), 3.95; 95% confidence interval (CI), 2.65–5.90], breast-feeding for ≤2 months total (OR 3.26; 95% CI 1.96–5.42), presence of ≥1 school age siblings (OR 2.85; 95% CI 1.88–4.33), ≥4 residents and visitors at home (discounting school age siblings and the case/control him/herself) (OR 1.91; 95% CI 1.19–3.07) and a family history of wheezing (OR 1.90; 95% CI 1.19–3.01). In premature infants born 33–35 WGA, certain underlying risk factors significantly increase the risk of RSV-related respiratory infection and hospitalization. Premature infants 33–35 WGA with additional risk factors should be considered for RSV prophylaxis with palivizumab.